3-year Postdoc in Glycoengineered Exosome-based Gene Therapy for Cancer

A 3-year Postdoc position for an experienced is available within the research group ‘Biotherapeutic Glycoengineering and Immunology’ headed by Professor Steffen Goletz and is funded by a NNF Distinguished Innovator grant. Our research group belongs to the Section of Medical Biotechnology at the Department of Biotechnology and Biomedicine. 

In our research group, we apply and develop advanced next generation antibody engineering as well as cellular and molecular glycoengineering technologies to elucidate the role of glycosylation's within complex immunological and disease networks and to generate novel exosome-, cell-, and multi specific antibody-based therapeutic approaches and drug candidates. Our main therapeutic interest is within immuno-oncology as well as infectious and lung diseases. One key focus lies within cell-based glycoengineering of extracellular vesicles for superior gene therapy and the design and development of their manufacturing processes. Further focus areas are within next generation antibody engineering with bi-/multi specific and multimodal antibody constructs, phage display technologies, molecular and cellular glycoengineering using gene-editing, exosome-, NK- and DC- cell based therapies and their mammalian bioprocess engineering and manufacturing. We also have a strong focus on innovation and entrepreneurship.

Responsibilities and qualifications
You as the experienced Postdoc will work within the NNF Distinguished Innovator grant "Precision targeting glycoengineered exosomes for cancer gene therapy" obtained by Prof. Steffen Goletz. The position in this innovation project will be collaboratively embedded in our strong multidisciplinary team with Senior scientists, postdocs, PhD students and technicians, to drive this high potential novel technology towards therapeutic application. 

You as the postdoc candidate must be extensively trained and experienced in cancer gene therapy (siRNA, mRNA, CRIPSR-based gene editing), in vitro 2D- and 3D cancer models, in vivo cancer xenotransplant mice models (with according to certifications), and assessment of therapeutics in preclinical cancer models. Besides the necessity of high motivation and excellent communication and collaboration skills, you ideally have a strong background and experience within human or mammalian cell engineering, antibody and single-domain antibody engineering and discovery, exosomes as drug delivery tools, and their production in mammalian systems, as well as immune-oncology. Prior successful postdoctoral research in the above area is highly advantageous.

Furthermore, as a formal qualification, you must hold a relevant PhD degree for the topic.

We offer
DTU is a leading technical university globally recognized for the excellence of its research, education, innovation and scientific advice. We offer a rewarding and challenging job in an international environment. We strive for academic excellence in an environment characterized by collegial respect and academic freedom tempered by responsibility. 

Further information 
Further information may be obtained from Prof. Steffen Goletz (sgoletz@dtu.dk), DTU Bioengineering.

You can read more about DTU Bioengineering at www.bioengineering.dtu.dk.

If you are applying from abroad, you may find useful information on working in Denmark and at DTU at DTU – Moving to Denmark.

Application procedure
Your complete online application must be submitted no later than 6 April 2025 (23:59 Danish time).

To view the full announcement and to apply please click on the 'Apply' button above.

Advert information